- $137.05m
- -$42.83m
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
U.S. STOCKS ON THE MOVE-Vicor, Thor Industries, Lennar
Brief: Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback
Compass falls after FDA recommends fresh trial before marketing application submission
Compass Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Compass Therapeutics Q2 net loss widens on higher R&D and G&A costs
U.S. RESEARCH ROUNDUP-Danaher, GM, MSCI
U.S. RESEARCH ROUNDUP-IBM, Lumentum Holdings, TransDigm Group
Compass Therapeutics Q1 net loss widens on higher R&D, G&A costs
U.S. RESEARCH ROUNDUP-Commvault Systems, Domino's Pizza, Organon & Co
U.S. STOCKS ON THE MOVE-Domino's Pizza, Veradermics, Peloton
Compass Therapeutics falls after cancer drug fails overall survival trial goal
Brief: Compass Therapeutics Inc. Tovecimig Plus Paclitaxel Improves Median Pfs To 4.7 Months Versus 2.6 Months
NASDAQ RESUMED AT 08:05 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM
Compass Therapeutics' 2025 net loss widens as R&D costs jump
Brief: Compass Therapeutics Provides Corporate Update
Brief: Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)